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by cellular 3′-5′ exonucleases, which may contribute to its 
greater potency.[3] Lamivudine is either formulated alone as a 
tablet/oral formulation or in combination with zidovudine. 
The spectroscopic method for assay of lamivudine is not 
official in any pharmacopoeia.[4–6] A few high-performance 
thin-layer chromatography (HPTLC) and high-performance 
liquid chromatography (HPLC) techniques have been 
suggested for analysis of the formulation.[7] HPLC is the 
most widely used technique for the estimation of lamivudine 
in human plasma, saliva, cerebrospinal fluid, and human 
blood cells, as well as for studying the drug metabolites in 
the urine.[8] The suggested HPTLC and HPLC methods 
for assay of lamivudine are expensive and need complex 
INTRODUCTION
Lamivudine, (2R-cis)-4-amino-1-[2-(hydroxymethyl)-
1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone,[1] is a synthetic 
nucleoside analogue with activity against the human 
immunodeficiency virus (HIV) and hepatitis B virus   
(HBV).[2] The molecule has two chiral centers and is 
manufactured as the pure 2R, cis(–)-enantiomer. The 
racemic mixture from which lamivudine originates has 
antiretroviral activity but is less potent and substantially 
more toxic than the pure (–)-enantiomer. Compared with the 
(+)-enantiomer, the phosphorylated (–)-enantiomer is more 
resistant to cleavage from nascent RNA/DNA duplexes 
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A rapid, simple, accurate, and economical spectrophotometric method has been developed and validated for 
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correlation coefficient being more than 0.999. The relative standard deviation of the replicate determination was 
about 0.5%. The percent recovery was within the range of 98%–102%, indicating insignificant interference from 
the other ingredients in the formulation. The method can be applied for the routine QC quantitation of lamivudine 
in API and tablet formulation.
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and sophisticated instrumentation.[8] Lamivudine can also 
be determined by Reverse Phase-HPLC method with lesser 
runtime, but the aforementioned drawback still persists.[9] 
One of the first methods for visible spectrophotometric 
determination of lamivudine was based on the colored 
condensation products of aromatic aldehydes;[10] this 
method suffers from a drawback as the interference from 
the excipients is more since the determination is carried 
out at much shorter wavelengths. It is also reported that 
lamivudine can also be assayed by titrimetric methods based 
on diazocoupling, redox reaction using Folin-Ciocalteu 
reagent, and redox-complexation reaction using ferric 
chloride-orthophenanthroline.[11] However, the above 
mentioned titrimetric methods are reported to suffer from 
disadvantages like unstablity of the reagents, high cost 
of the chemicals, reduced sensitivity, etc.[12] The present 
research work describes a UV spectrophotometric method 
for estimation of lamivudine in API and its pharmaceutical 
preparation.
MATERIALS AND METHODS
Elico SL-159 UV-visible spectrophotometer equipped 
with a matched quartz cells ultrasonic bath was used to 
carry out the assay. The solvent used for the assay was 
spectroscopic-grade methanol.
Evaluation of wavelength 
About 10 µg/mL of lamivudine drug substance was 
accurately prepared in spectroscopic-grade methanol 
solvent. This preparation was then scanned in the 200–350 
nm UV region. The wavelength maxima (λmax) was observed 
at 270 nm and this wavelength was adopted for absorbance 
measurement [Figure 1]. 
Standard preparation
Accurately weighed 100 mg of lamivudine test standard 
was transferred to a volumetric flask containing 25 mL 
of methanol solvent. This was sonicated for about 5 min 
to dissolve it and the resultant solution was diluted to 100 
mL with methanol solvent. Ten milliliters of this standard 
preparation was transferred to another volumetric flask and 
then diluted to 100 mL with methanol solvent. 
Sample preparation
Ten tablets from the marketed sample were weighed and 
crushed uniformly with the help of a mortar and pestle. 
An accurately weighed powder sample equivalent to 
100 mg of lamivudine was transferred into a volumetric 
flask containing 25 mL methanol solvent. The contents 
were sonicated for about 5 min so that the dissolution is 
enhanced and is completed in 15 min. Ten millititers of 
the supernatant solution was then taken and diluted to 100 
mL with methanol solvent [Table 1]. 
Procedure
The baseline correction on the UV spectrophotometer 
was performed using methanol as blank solvent in both 
reference and sample quartz cells. The aim was to obtain the 
absorbance of the standard (10 µg/mL of lamivudine) and 
sample preparations at 270 nm and determine the content 
of C8H11N3O3S in each tablet.
VALIDATION
The method was validated for specificity, linearity, accuracy, 
ruggedness, and solution stability.
Specificity: The specificity of the method was established 
by measuring the interference, if any, observed due to the 
methanol solvent at the wavelength maxima of lamivudine. 
No significant absorbance due to methanol was observed 
at 270 nm [Figure 1].
Linearity
The linearity of the method was established by determining 
Table 1: Analysis data of tablet formulation
Sample Label claim 
(mg/tablet)
Amount 
obtained  
(mg/tablet)
Percentage Relative standard 
deviation  
(n=6)
Brand I 100 98.9 98.9 0.38%
Brand II 100 99.2 99.2 0.42%
Figure 1: UV scan of lamivudine in methanolUV analysis of lamivudine
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the absorbance of different concentrations of lamivudine 
drug substance over a range of 50% (5 µg/mL) to 150% 
(15 µg/mL) of the normal sample preparation. Each level 
was measured in triplicate.
The calibration curve, as plot of absorbance vs concentration 
in µg/mL of lamivudine, was found to be rectilinear for 
5, 8, 10, 12, and 15 µg/mL concentrations of lamivudine. 
The correlation coefficient was found to be more than 
0.9998 [Figure 2].
Precision 
The assay of the same batch was performed in six replicates 
and the percentage relative standard deviation (%RSD) 
measured. The %RSD was found to be not more than 
0.5%. 
Accuracy
The accuracy of the method was established by adding 
the lamivudine test standard solution of the pre-analyzed 
tablet formulation. The analysis at each level was performed 
in triplicate and the mean recovery of lamivudine was 
measured. The percent recovery at each level was found 
to be well within the range of 98.0%–102.0%, indicating 
insignificant interference from the excipients.
Ruggedness
The ruggedness of the method was established by having 
the precision study performed on another instrument by 
another analyst. The cumulative %RSD for content of 
lamivudine for the samples of precision and ruggedness 
study were found to be not more than 1.0%.
Solution stability
The absorbance of the same sample solution at the initial 
stage and intervals of 4 hours, 8 hours, 12 hours, and 24 
hours were measured and the cumulative %RSD determined. 
The %RSD was found to be not more than 2.0%
CONCLUSION
The proposed method for the assay of the popular anti-
retroviral agent lamivudine in the commercially available 
tablet formulation is simple, accurate, economical, and 
rapid. It can be easily adopted for routine quality control 
for monitoring the assay in the API, in-process samples, 
and the finished tablet formulation. The method can be 
extended for studying the dissolution profile.
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